SDS

Acute oral toxicity
LD50 (female rat) > 2,000 mg/kg
Acute inhalation toxicity
LC50 (male/fe
male combined rat) > 5.1 mg/l
Exposure time: 4 h
Determined in the form of a respirable aerosol.
(actual)
LC
50 (male/
female combined rat) > 20.4 mg/l
Exposure time: 1 h
Determined in the form of a respirable aerosol.
Extrapolated from the 4 hr LC50.
(actual)
Acute dermal toxicity
LD50
(male/fe
male combined rat) > 4,000 mg/kg
Skin irritation
Slight irritation (rabbit
)
Eye irritation
Minimally irritating. (rabbit
)
Sensitisation
Non-sensitiz
ing. (guinea pig)
Assessment repeated dose toxicity
Imidacloprid did not cause specific target organ toxicity
in experimental animal studies.
Tau-fluvalinate did not cause specific target organ toxicity in experimental animal studies.
Tebuconazole did not cause specific target organ toxicity in experimental animal studies.
Assessment Mutagenicity
Imidacloprid was not mutagenic or genotoxic based on the overall weight of evidence in a battery of in
v
itro and in vivo tes
ts.
Tau-fluvalinate was not mutagenic or genotoxic in a battery of in vitro and in vivo tests.
Tebuconazole was not mutagenic or genotoxic in a battery of in vitro and in vivo tests.
Assessment Carcinogenicity
Imidacloprid was not carcinogenic in lifetime feeding studies in rats and mice.
Tau
-fluvalinate was
not carcinogenic in lifetime feeding studies in rats and mice.
Tebuconazole caused at high dose levels an increased incidence of tumours in mice in the following
organ(s): liver. The mechanism of tumour formation is not considered to be relevant to man.
ACGIH
None.
NTP
None.
IARC
None.
OSHA
None.
Assessment toxicity to reproduction
Imidacloprid caused reproduction toxicity in a two-generation study in rats only at dose levels also toxic
SBM LIFE SCIENCE CORP.
SAFETY DATA SHEET
BIOADVANCED SCIENCE-BASED
SOLUTIONS 3-IN-1 INSECT, DISEASE &
MITE CONTROL CONCENTRATE
Version 1.0 / USA
102000015315
7/11
Revision Date: 01/31/2019